SCHEMBL4597626

SCHEMBL4597626

COC(=O)c1ccc(Oc2cc(C)c(C=O)cn2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.53
ALDH1A1 P00352 4/20 0.51
TSHR P16473 2/20 0.49
NPSR1 Q6W5P4 1/20 0.49
GAA P10253 2/20 0.48
ERN1 O75460 3/20 0.46
KDM4E B2RXH2 3/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
MAPK1 P28482 2/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
RAB9A P51151 1/20 0.45
KLF5 Q13887 1/20 0.45
MAPT P10636 2/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5575384 0.81 ALDH1A1 (0.50) LMNAALDH1A1TSHRNPSR1GAA
SCHEMBL4596521 0.78 KDM4E (0.65) LMNAALDH1A1TSHRNPSR1GAA
SCHEMBL4597491 0.78 ALDH1A1 (0.53) LMNAALDH1A1TSHRNPSR1GAA
SCHEMBL4597485 0.78 ALDH1A1 (0.56) LMNAALDH1A1TSHRNPSR1GAA
SCHEMBL4597993 0.77 ALDH1A1 (0.49) LMNAALDH1A1TSHRNPSR1GAA
SCHEMBL4597531 0.75 ALDH1A1 (0.51) LMNAALDH1A1TSHRNPSR1GAA
SCHEMBL4597946 0.74 ALDH1A1 (0.54) LMNAALDH1A1TSHRNPSR1GAA
SCHEMBL4597845 0.74 LMNA (0.50) LMNAALDH1A1TSHRNPSR1GAA
SCHEMBL8702460 0.74 ALDH1A1 (0.57) LMNAALDH1A1GAAERN1KDM4E
SCHEMBL21656526 0.73 LMNA (0.63) LMNAALDH1A1TSHRNPSR1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1924265-A2 CHEMOKINE RECEPTOR BINDING COMPOUNDS Genzyme Corporation (US) 2008-05-28 EP disclosed
US-20070066624-A1 Chemokine receptor binding compounds ANORMED, INC. (CA) 2007-03-22 US disclosed
US-20070066624-A1 Chemokine receptor binding compounds ANORMED, INC. (CA) 2007-03-22 US disclosed
US-20070066624-A1 Chemokine receptor binding compounds ANORMED, INC. (CA) 2007-03-22 US disclosed
WO-2007022371-A2 CHEMOKINE RECEPTOR BINDING COMPOUNDS GENZYME CORPORATION (US) 2007-02-22 WO disclosed
WO-2007022371-A2 CHEMOKINE RECEPTOR BINDING COMPOUNDS GENZYME CORPORATION (US) 2007-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070066624-A1 Chemokine receptor binding compounds CCR5, CCR4, CCR1 LMNA 4700/4885ALDH1A1 3484/4885TSHR 2129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.